BioNTech SE (BNTX)
Pre-market: 04:38AM EDT
| Previous close | 281.96 |
| Open | 289.50 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1100 |
| Day's range | 276.68 - 297.72 |
| 52-week range | 54.10 - 297.72 |
| Volume | 4,025,303 |
| Avg. volume | 3,118,343 |
| Market cap | 69.138B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 52.27 |
| EPS (TTM) | 5.48 |
| Earnings date | 09 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 200.87 |
- Editor's pickYahoo Finance Video
Doctor on COVID-19 vaccination: ‘Too little too late, better late than never, if anything it all counts’
Dr. Calvin Sun,The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
- Motley Fool
After Covid, BioNTech Has Its Sights Set on Malaria
BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is...
- Motley Fool
Why BioNTech Rose as Much as 5% Today
Coronavirus stock BioNTech (NASDAQ: BNTX) was a winner on Monday. BioNTech announced Monday that it has launched a project aimed at developing a malaria vaccine based on the messenger RNA (mRNA) technology that underpins BNT162b2. The biotech said this program, "will assess multiple vaccine candidates featuring known Malaria targets ... as well as new antigens discovered in the pre-clinical research phase."
